

USHP Annual Meeting  
Saturday, August 23, 2014  
Intermountain Medical Center, Doty Education Center  
5121 South Cottonwood Street  
Murray, Utah 84107

## 2014 Registration

Option 1 – Fill out this form and mail with check to:  
USHP, PO Box 58356, Salt Lake City, Utah 84158  
Registration must be postmarked by August 9, 2014

Option 2 – Register online and pay via credit card or paypal at [www.ushp.org](http://www.ushp.org)

Space is Limited – Register Early!

Name:

---

Mailing Address:

---

City, State, Zip:

---

Preferred Phone:

Dietary Needs:

---

Email Address:

---

CPE Monitor ID# (required)

Birth Month/Day (required)

/

---

Note: CPE Monitor ID, Birth Month/Day required for ACPE credit

After August 9<sup>th</sup>, add \$25 to the below published price. An e-mail confirmation will be sent to the above indicated address.

### Pricing Schedule

	Member	Non-Member
Pharmacists	___ \$100	___ \$175
Technician	___ \$50	___ \$100
Student	___ \$30	___ \$45

## **Meeting Agenda**

USHP Annual Meeting

August 23, 2014

Intermountain Medical Center, Doty Education Center

5121 South Cottonwood Street

Murray, Utah 84107

<b>7:00 AM – 8:00 AM</b>	<b>Registration, Check-In &amp; Breakfast</b>	
<b>8:00 AM – 8:45 AM</b>	<b>Welcome/ Business Meeting (Awards, Install Officers)</b>	
<b>8:45 AM – 9:45 AM</b>	<b>ASHP Guest Lecturer: ASHP Update: Trends, Developments and Future Implications (P/T)</b> Beverly Black, MHSA, CAE	
<b>9:45 AM – 10:00 AM</b>	<b>Break/Snacks/Exhibitors</b>	
<b>10:00 AM – 11:00 AM</b>	<b>Keynote Presentation: Understanding the Statin Focus of New Cholesterol Guidelines (P/T)</b> Joseph Saseen, PharmD, FASHP, FCCP, FNLA, BCPS, CLS	
<b>11:00 AM – 12:00 PM</b>	<b>Drug Diversion: Tales from the Vault (P/T)</b> Heidi Bragg, MBA, RPh	
<b>12:00 PM – 1:00 PM</b>	<b>Lunch/Exhibitors/Poster Session</b>	
<b>1:00 PM – 2:00 PM</b>	<b>Personalizing Antibiotic Therapy for the Critically Ill Patient via <math>\beta</math>-lactam Continuous Infusion (P)</b> Wayne Shipley, PharmD, BCPS	<b>As the Inventory Turns (P/T)</b> Steffanee Wanlass, CPhT
<b>2:05 PM – 3:05 PM</b>	<b>Intellectual Debates in Infectious Diseases (ID<sup>2</sup>) (P)</b> Russell Benefield, PharmD, BCPS Whitney (Redding) Buckel, PharmD	<b>Antidepressants in Pregnancy and While Breastfeeding: Do We Really Need to be so Concerned? (P/T)</b> Julia Robertson, CPM
<b>3:10 PM – 4:10 PM</b>	<b>Preventing Cancer and Saving Lives One Steak at a Time (P/T)</b> Regan Healy, PharmD, BCOP	<b>Toxicology Update – New Drugs and Antidotes (P/T)</b> Amberly Johnson, PharmD
<b>2:10 PM – 4:10 PM</b>	<b>Student Programming</b> <b>“Residency Program Overview and A Day in the Life of a Resident”</b>	

**P = Accredited for Pharmacists**

**T = Accredited for Technicians**

**The target audience is Pharmacists and Pharmacy Technicians.**

**All educational activities are knowledge-based activities**

## Educational Objectives

8:45 AM

“ASHP Update: Trends, Developments and Future Implications”

Beverly Black, MHSA, CAE

Director of the Affiliate Relations Division, ASHP

0167-0000-14-001-L04-P/T

Objectives (pharmacists and technicians)

1. Describe the current federal efforts surrounding obtaining Provider Status for pharmacists
  2. Describe current state legislation and regulation surrounding Provider Status at the state level
  3. Understand the roles of federal and state federal and regulatory actions pertaining to Provider Status
  4. Describe how the recently-passed federal legislation on compounding will affect practice
  5. Describe current state legislation and regulation surrounding compounding at the state level
  6. List the resources available through ASHP and other state and federal organizations to help advance pharmacy practice in the ambulatory setting
- 

9:45 AM

“Understanding the Statin Focus of New Cholesterol Guidelines”

Joseph Saseen, PharmD, FASHP, FCCP, FNLA, BCPS, CLS

Professor and Vice Chair, Department of Clinical Pharmacy

Professor, Department of Family Medicine

University of Colorado

0167-0000-14-002-L01-P/T

Objectives (pharmacists)

1. Describe the 4 patient populations identified by the 2013 ACC-AHA blood cholesterol guidelines as those who benefit from statin therapy
2. Contrast the 2013 ACC-AHA blood cholesterol guidelines to other approaches to treating patients with hyperlipidemia
3. Review the ASCVD risk calculator and how it is used to determine need for statin therapy in primary prevention patients, including those with diabetes
4. Differentiate high-intensity from moderate-intensity statin therapy

Objectives (technicians)

1. List the 4 patient populations identified by the 2013 ACC-AHA blood cholesterol guidelines as those who benefit from statin therapy
  2. Explain the overall evidence-based benefits of using statin therapy
  3. Identify patient characteristics needed to use the ASCVD risk calculator
  4. Categorize statin therapies as high, moderate or low intensity based on their dose
-

11:00 AM

“Drug Diversion: Tales from the Vault”

Heidi Bragg, MBA, RPh

Director, Regulatory Compliance, Cardinal Health Pharmacy Services

0167-0000-14-009-L03-P/T

Objectives (pharmacists)

1. Compare and contrast state and federal regulatory requirements for reporting drug diversion
2. Evaluate the existing system in their workplace for detection, investigation and reporting of drug diversion incidents
3. Identify areas of risk for drug diversion and describe methods to mitigate the risks

Objectives (technicians)

1. Define drug diversion
  2. Explain the state and federal regulations governing pharmacies related to drug diversion
  3. Cooperate with pharmacy management in drug diversion investigations
- 

13:00 PM

“Personalizing Antibiotic Therapy for the Critically Ill Patient via  $\beta$ -lactam Continuous Infusion”

Wayne Shipley, PharmD, BCPS

Critical Care Clinical Pharmacist, University of Utah Hospital

0167-0000-14-003-L01-P

Objectives (pharmacists only)

1. List four criteria when considering a continuous antibiotic infusion for a patient
  2. Describe three characteristics of drugs that lend themselves to use for a continuous infusion
  3. Outline a practice strategy for initiating and monitoring a  $\beta$ -lactam continuous infusion with therapeutic drug monitoring
  4. Evaluate the evidence for implementing a  $\beta$ -lactam continuous infusion as a standard of care for the critically ill
- 

13:00 PM

“As the Inventory Turns”

Steffanee Wanlass, CPhT

Division Pharmacy Inventory & Purchasing Analyst, Parallon Supply Chain Solutions

0167-0000-14-004-L04-P/T

Objectives (pharmacists)

1. Demonstrate savings with improved inventory management practices
2. Identify ways to reduce inventory through communication of clinical initiatives
3. Outline strategies to reduce inventory by performing a visual inspection of your pharmacy

Objectives (technicians)

1. Describe the key focus areas of good inventory management
  2. Identify ways to increase inventory turns
  3. Outline a plan on inventory reduction strategies that can be worked into daily practices
- 

14:05 PM

“Intellectual Debates in Infectious Diseases (ID<sup>2</sup>)”

Russell Benefield, PharmD, BCPS

Infectious Diseases Clinical Pharmacist, University of Utah Hospital

Whitney (Redding) Buckel, PharmD

Infectious Diseases Clinical Pharmacist, Intermountain Medical Center

0167-0000-14-005-L01-P

Objectives (pharmacists only)

1. Define minimum inhibitory concentration (MIC) and describe common laboratory methods used to determine MICs
  2. List limitations in MIC testing interpretation for methicillin-resistant *Staphylococcus aureus* (MRSA)
  3. Formulate an antibiotic regimen for the treatment of MRSA bacteremia with a vancomycin MIC of 2
  4. Given a *Candida* species, identify whether it is likely susceptible to fluconazole and/or echinocandins
  5. Given a patient case with candidemia, justify the initial use of fluconazole or an echinocandin based on *Candida* species and patient host factors
  6. Choose two non-pharmacologic strategies to incorporate into a therapeutic plan for a patient with MRSA bacteremia and candidemia
- 

14:05 PM

“Antidepressants in Pregnancy and While Breastfeeding: Do We Really Need to be so Concerned?”

Julia Robertson, CPM

Program Manager, Utah Department of Health, Pregnancy Risk Line/Mother to Baby Utah

0167-0000-14-006-L01-P/T

Objectives (pharmacists)

1. Describe the stages of fetal embryology
2. Outline the risks and benefits of antidepressant use in pregnancy
3. Identify which antidepressants can be safely used during breastfeeding
4. List potential side-effects for an infant when antidepressants are used while breastfeeding

Objectives (technicians)

1. Describe the different stages of fetal development
  2. Differentiate the various pregnancy categories of a medication
  3. List two medications that are considered safe during pregnancy
-

15:10 PM

“Preventing Cancer and Saving Lives One Steak and a Time”

Regan Healy, PharmD, BCOP

Malignant Hematology and Oncology Clinical Pharmacist, LDS Hospital

0167-0000-14-008-L01-P/T

Objectives (pharmacists)

1. Conduct appropriate patient education on modifiable cancer risk factors
2. Specify which cancer screening techniques have proven to reduce cancer-related mortality for breast, prostate, lung and colorectal cancers
3. Locate and describe current cancer screening guidelines for the early detection of breast, prostate, lung, and colorectal cancers
4. Devise an approach to educate patients about ongoing cancer screening controversies

Objectives (technicians)

1. Identify modifiable cancer risk factors
  2. Locate current cancer screening guidelines for patients and healthcare professionals
  3. Describe current cancer screening controversies
- 

15:10 PM

“Toxicology Update – New Drugs and Antidotes”

Amberly Johnson, PharmD

Fellow in Applied and Clinical Toxicology, Utah Poison Control Center, University of Utah College of Pharmacy

0167-0000-14-007-L01-P/T

Objectives (pharmacists)

1. Describe the mechanism of action of high dose insulin euglycemia therapy (HIE) in a calcium channel blocker/beta blocker poisoning
2. Describe the mechanism of action of Intralipid™ for lipid rescue in a lipophilic drug poisoning
3. Describe the mechanism of action of methylene blue in cardiogenic shock resulting from a poisoning
4. Evaluate the available literature for the use of HIE, lipid rescue, and methylene blue in poisoned patients

Objectives (technicians)

1. List uses of high dose insulin euglycemia therapy (HIE), Intralipid™, and methylene blue in the treatment of the poisoned patient
2. Identify 2 new substances of abuse in the United States
3. Identify common adverse effects of 2 new drugs of abuse
4. State common adverse effects of HIE, Intralipid™, and methylene blue

## Conference Details

**Registration:** Registration fees are discounted before August 9, 2014. To register, complete the registration form and pay by credit card (online only) or send a check to: USHP, PO Box 58356, Salt Lake City, Utah 84158. Space is Limited! Register Early. Registration fee includes admittance to all programming, exhibits, and group meal functions.

Registrations received after the August 9<sup>th</sup> deadline or on site are subject to a \$25 additional processing fee.

**CE Credit:** To obtain up to 6 credits of continuing pharmacy education credit (.60 CEUs), the participant must attend the conference, check in at the registration desk, complete and turn in the attendance and evaluation forms, and pass each assessment test with a 75% or higher score. Attendance forms not turned in on site will not be accepted for credit. All credit will be awarded through participants' CPE Monitor accounts. Credits will be uploaded within 60 days after the program.

**Cancellation Policy:** To receive partial or full refund, registrants must contact USHP in writing prior to August 9, 2014. Requests made after August 9<sup>th</sup> may not be considered.

**Exhibits:** The exhibit area offers an opportunity to learn about the latest from the pharmaceutical industry. Representatives from pharmaceutical manufacturers, wholesalers and others may be on hand to demonstrate new products and services.

**Special Assistance:** It is USHP's policy to comply with the American's with Disabilities Act. If you have any special needs or services while attending, please contact USHP no later than August 9, 2014 at [ushp@ushp.org](mailto:ushp@ushp.org).

**Parking:** Parking is complimentary and is located adjacent to the building. Directions to the facility will be available on the USHP website ([www.ushp.org](http://www.ushp.org)) prior to the conference.

**Accommodations:** If you are in need of overnight accommodations, please USHP at [ushp@ushp.org](mailto:ushp@ushp.org).

**No grant funding has been sought for this educational program**



The Utah Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.